Search
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalTherefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach. … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].
Olsalazine
go.drugbank.com/drugs/DB01250Approved[A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene
Risedronic acid
go.drugbank.com/drugs/DB00884ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
Ginkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical_Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]
Rusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Teriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]
Micafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.